CRISM Therapeutics Corporation
CRTX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.07 | 0.01 |
| FCF Yield | -22.57% | 0.00% | -130.27% | -0.04% |
| EV / EBITDA | -3.89 | 0.00 | 5.13 | 9.53 |
| Quality | ||||
| ROIC | -69.31% | 0.00% | -0.10% | -6.16% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.93 | – | 18.00 | 1.52 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 100.00% | -94,578.35% | 99.97% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | 0.00 | 6.38 | 14.99 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,150.52 | 0.00 | -848.31 | 0.00 |